Acquire future economic rights (royalties, milestones) associated with pre-commercial therapeutic candidates. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $48.6M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 15.9× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 67% of them.
Analysts' average target sits 3% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
The net profit margin is 61% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 8% a year on average.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 37/100.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.